Eledon Pharmaceuticals

Eledon Pharmaceuticals will present updated clinical data from approximately 30 kidney transplant recipients in their ongoing Phase 1b study of tegoprubart at the World Transplant Congress in San Francisco.

Sernova Biotherapeutics and Eledon Pharmaceuticals announced a collaboration to evaluate tegoprubart, an anti-CD40L antibody, in Sernova's Phase 1/2 Cell Pouch Bio-hybrid Organ clinical trial for type 1 diabetes.

Massachusetts General Hospital successfully performed its second pig-to-human kidney transplant using Eledon's tegoprubart as a key immunosuppressant, with the patient now off dialysis after two years.

Eledon Pharmaceuticals completed Phase 2 BESTOW trial enrollment for tegoprubart in kidney transplantation, with topline results expected in Q4 2025.

Initial data from a University of Chicago study show that tegoprubart, an anti-CD40L antibody, helped two out of three patients achieve insulin independence after islet transplantation.

Tegoprubart, an experimental immunosuppressant, demonstrates encouraging results in islet cell transplants for Type 1 diabetes, potentially reducing or eliminating the need for insulin injections.

Marlaina Goedel, a 30-year-old woman from Illinois, has been cured of type 1 diabetes after 25 years of insulin dependence through a pioneering islet cell transplant.

Eledon Pharmaceuticals' tegoprubart, as part of an immunosuppression regimen, enabled insulin independence in two of three type 1 diabetes subjects after islet transplantation.

Tegoprubart, an experimental immunosuppressant, demonstrates encouraging results in islet cell transplantation for Type 1 diabetes, potentially reducing or eliminating the need for insulin injections.

Eledon Pharmaceuticals reports that tegoprubart, as part of an immunosuppression regimen, enabled insulin independence in two of three type 1 diabetes subjects after islet transplantation.